Search

Your search keyword '"Adam Ammar"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Adam Ammar" Remove constraint Author: "Adam Ammar"
122 results on '"Adam Ammar"'

Search Results

1. Global neurosurgical workforce density—you cannot improve what you do not measure

2. Access to training in neurosurgery (Part 1): Global perspectives and contributing factors of barriers to access

3. Access to training in neurosurgery (Part 2): The costs of pursuing neurosurgical training

5. Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers.

6. Abstract B024: Leveraging synthetic lethality across EP300-mutant solid cancers through selective CBP degradation

7. Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers

8. Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

10. Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers

12. Abstract 2122: The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AML

13. Supplemental Table 1 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

14. Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

15. Supplemental Figure 1 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

16. Supplemental Figure 2 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

17. Data from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

18. Supplemental Methods from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

19. Supplemental Figure 3 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

20. Supplemental Table 2 from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

21. Global Neurosurgery Advocacy

22. Advancing Relevant Research

23. Working Out of the Silo of Global Neurosurgery

25. Factors predicting complications following cranioplasty

26. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

29. Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML

30. Global Neurosurgery: A call to Action

31. Suturing the Gaps in Global Health Security: Key Messages from a Panel along the Sidelines of the United Nations General Assembly

32. Global neurosurgical workforce density—you cannot improve what you do not measure

33. Use of the Image Guided Minimally Invasive BrainPath System to Evacuate Spontaneous Cerebellar Hemorrhages

34. African Neurosurgery Research: A Scientometric Analysis of the Top 115 Most Cited Articles

35. Hierarchy of Scientific Evidence and Thematic Analysis of African Neurosurgery Research – a Scoping Review

36. An Assessment of Global Neurotrauma Prevention and Care Delivery: The Provider Perspective

37. Out-of-pocket Cost of Essential Neurosurgical Procedures: A Systematic Review

38. Out-of-pocket Cost of Neurosurgical Bellwether Procedures: A Systematic Review

39. Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers

40. Open craniofacial reconstruction for coronal craniosynostosis

41. Letter to the Editor: COVID-19 & Neurosurgical Training in Low- and Middle-Income Countries

42. Managing a Specialty Service During the COVID-19 Crisis: Lessons From a New York City Health System

43. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

44. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

47. The limits of endoscopic endonasal approaches in young children: a review

48. Use of Google Glass to Enhance Surgical Education of Neurosurgery Residents: 'Proof-of-Concept' Study

50. Trends in the Use of Bone Morphogenetic Protein-2 in Adult Spinal Deformity Surgery: A 10-Year Analysis of 54 054 Patients

Catalog

Books, media, physical & digital resources